Do Current Asthma-Preventive Measures Appropriately Face the World Health Organization's Concerns: A Study Presentation of a New Clinical, Prospective, Multicentric Pediatric Asthma Exacerbation Cohort in Germany

Frontiers in Pediatrics

article

Malik Aydin¹  Ella A. Naumova³  Soeren Lutz⁴  Almut Meyer-Bahlburg⁵  Wolfgang H. Arnold³  Florian Kreppel⁶  Anja Ehrhardt⁷  Jan Postberg¹  Stefan Wirth¹ 

[1] Center for Child and Adolescent Medicine, Center for Clinical and Translational Research (CCTR), Helios University Hospital Wuppertal, Witten/Herdecke University;Clinical Molecular Genetics and Epigenetics, Faculty of Health, Center for Biomedical Education and Research (ZBAF), Witten/Herdecke University;Department of Biological and Material Sciences in Dentistry, Faculty of Health, Witten/Herdecke University;Children's Hospital, Helios Hospital Niederberg, Teaching Hospital of the Essen University Hospital;Department of Pediatric Rheumatology and Immunology, Children's Hospital, University Medicine Greifswald;Chair for Biochemistry and Molecular Medicine, Faculty of Health, Center for Biomedical Education and Research (ZBAF), Witten/Herdecke University;Faculty of Health, Center for Biomedical Education and Research (ZBAF), Institute of Virology and Microbiology, Witten/Herdecke University

关键词: asthma;    allergy;    childhood;    exacerbation;    epigenome;    biomarker;    healtcare;   

DOI  :  10.3389/fped.2020.574462

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

In summer 2017, the World Health Organization published 10 facts on asthma, which is known as a major non-communicable disease of high clinical and scientific importance with currently several hundred million people—with many children among them—suffering from air passages inflammation and narrowing. Importantly, the World Health Organization sees asthma as being underdiagnosed and undertreated. Consequently, much more efforts in clinical disease management and research need to be spent on reducing the asthma-related health burden. Particularly, for young approximately 6 months aged patients presenting recurrent bronchitic respiratory symptoms, many parents anxiously ask the doctors for risk prognosis for their children's future life. Therefore, we urgently need to reevaluate if the current diagnostic and treatment measures are in concordance with our yet incomplete knowledge of pathomechanisms on exacerbation. To contribute to this increasing concern worldwide, we established a multicentric pediatric exacerbation study network, still recruiting acute exacerbated asthmatics (children >6 years) and preschool asthmatics/wheezers (children <6 years) since winter 2018 in Germany. The current study that has a currently population comprising 176 study participants aims to discover novel holistic entry points for achieving a better understanding of the poorly understood plasticity of involved molecular pathways and to define biomarkers enabling improved diagnostics and therapeutics. With this study description, we want to present the study design, population, and few ongoing experiments for novel biomarker research. Clinical Trial Registration : German Clinical Trials Register (Deutsches Register für Klinische Studien, DRKS): DRKS00015738.

【 授权许可】

CC BY